Immunotherapy cocktail shows promise against tough rectal cancers

NCT ID NCT06884670

Completed Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving a mix of immunotherapy drugs (tislelizumab and IL-2) plus chemotherapy before surgery could shrink tumors more effectively in people with locally advanced rectal cancer. The trial involved 130 adults whose cancers had not spread but were hard to treat. The goal was to see if more patients could achieve a complete response, meaning no cancer remains at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (PD-1 inhibitor), Interleukin-2, Capecitabine, Oxaliplatin
What this could lead to: If successful, this combination could become a new standard neoadjuvant treatment, increasing the chance of complete tumor disappearance before surgery for rectal cancer patients.
What could go wrong: This is a phase 2 trial with only 130 participants, so results may not apply to all patients. The combination may cause more side effects than standard therapy, and the long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

Jiangsu province hospital

Nanjing, Jiangsu, 210029, China
Nanjing BenQ Hospital

Nanjing, Jiangsu, 210000, China
The Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, China
Xuzhou Central hospital

Xuzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.